ArticleVaccines2026

Evaluation of an In-House Developed Foot-and-Mouth Disease Virus SAT 3 Vaccine Strain Based on Antigen Productivity and Inactivation Kinetics for Commercial Feasibility.

Jae Young Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.